A striking disparity in survival rates emerges between genders in a study on anti-CTLA-4 treatment, with men showing a 20% survival rate compared to near 0% in the placebo group. The potential reasons for this difference may lie in immune response variations and dosing based on body weight, leading to men receiving higher doses than women. This raises important questions about how gender influences treatment outcomes in clinical studies.
